Novo Holdings

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Convergent Therapeutics is a clinical-stage biotechnology company focused on developing innovative radiopharmaceutical therapies specifically for prostate cancer. The company utilizes a proprietary dual-targeted radionuclide therapy technology, initially developed by Dr. Neil Bander from Weill Cornell Medicine, which is licensed from Cornell University. Its lead product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac. This therapy is designed to bind to the prostate-specific membrane antigen (PSMA) and, upon binding, internalize to deliver a potent radioactive payload directly into prostate cancer cells. CONV 01-α is protected by multiple U.S. and foreign patents, and if approved by the FDA, it would be the first antibody to deliver a radioisotope specifically for prostate cancer treatment, marking a significant advancement in cancer therapy. Convergent Therapeutics aims to explore dual-targeted combination strategies to enhance cancer treatment efficacy, leveraging various targeting agents and therapeutic doses.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies aimed at overcoming cancer treatment resistance and improving patient access to potentially curative options. The company aims to enhance treatment outcomes by addressing the limitations of existing therapies, which currently provide curative benefits to less than half of cancer patients. Its lead program, CRG-022, is a novel CAR T-cell product candidate that targets CD22, a tumor antigen prevalent in many B-cell malignancies. By tackling issues such as limited durability, safety concerns, and supply chain obstacles, Cargo Therapeutics is committed to advancing innovative solutions that make effective cancer treatments more accessible to patients.

Bluejay Therapeutics is a biopharmaceutical company dedicated to developing cures for infectious diseases, with a primary focus on chronic Hepatitis B. This condition poses a significant global health challenge, and the company aims to address the urgent need for effective treatments. Bluejay is advancing two innovative therapeutic approaches: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class oral small molecule inhibitors targeting HBsAg. These strategies are designed to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially leading to a functional cure for patients. Additionally, the company’s research encompasses therapeutic options for chronic Hepatitis D, further solidifying its commitment to improving immunity and recovery for individuals affected by serious viral and liver diseases.

Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

LEXEO Therapeutics is a biotechnology company that specializes in the development of gene therapies, particularly those utilizing adeno-associated virus (AAV) technology. The company’s pipeline includes both rare and non-rare monogenic diseases, with a strong emphasis on hereditary and acquired conditions that present significant unmet medical needs. LEXEO's lead programs and preclinical candidates are primarily developed in collaboration with Weill Cornell Medicine’s Department of Genetic Medicine. The company aims to advance its clinical programs toward commercialization while maintaining an ongoing research partnership with Weill Cornell to enhance its preclinical efforts. Through its innovative approach, LEXEO Therapeutics seeks to transform the treatment landscape for diseases that impose a substantial burden on patients and society.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

MapLight Therapeutics offers a platform designed to discover and develop therapeutics for brain disorders. It combines single-cell transcriptomics and optogenetics to identify novel drug targets and develop effective therapies for brain disorders.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster. They are targeting the growing need for throughput with robust solutions for clinical and large-scale proteomics, and they have a very ambitious business plan to bring their first products to market. They are basing their design on years of experience with nano-UHPLC R&D and application support, critically rethinking the necessary system architectures for successful sample separation before mass spectrometric analysis. Evosep aims to improve quality of life and patient care by radically innovating how protein based clinical diagnostics are performed, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 10 times faster and 100 times more robust than todays’alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population. This calls for fast sample processing and because such clinical samples, in the form of blood or biopsies, are much more crude that the relatively clean cell cultures used in basic research, very robust protocols and consumables are also required.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at treating life-threatening diseases. The company employs its proprietary Alphamer technology, which utilizes chemically synthesized molecules to redirect naturally occurring antibodies towards specific pathogens, enhancing the body's immune response to fight infections. Centauri's approach features a dual mechanism of action: a moiety that directly targets cell surface antigens and a glycan effector domain that activates a robust pre-existing polyclonal immune response. This response facilitates cell death through mechanisms such as complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has produced promising pre-clinical data, showcasing significant enhancements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, along with in vivo proof of concept data across multiple infection models.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Asgard Therapeutics is a private biotech company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Emerging as a spin-off from Lund University, the company utilizes its proprietary TrojanDC technology to initiate immune responses by leveraging the unique properties of professional antigen-presenting cells. This approach aims to create efficient and personalized gene therapy products that activate robust anti-cancer immune defenses. By offering off-the-shelf solutions, Asgard Therapeutics seeks to provide new treatment options for patients suffering from cancers that are resistant to traditional therapies, thereby expanding the possibilities for effective cancer treatment.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Aristea Therapeutics is a developer of novel therapies created for autoimmune diseases.The company's therapies include developing drugs, enabling inflammatory diseases patients to address their unmet medical needs.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Hummingbird Bioscience focuses on the development of innovative therapeutic antibody-based drugs aimed at addressing significant unmet needs in oncology and immuno-oncology. Utilizing a proprietary rational antibody discovery platform, the company leverages systems biology and computational methods to gain insights into disease mechanisms, guiding the discovery and engineering of new biotherapeutics. Hummingbird's pipeline includes promising drug candidates such as HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, both targeting cancer treatment. The company has formed strategic collaborations with organizations like Cancer Research UK and Amgen and has received a product development grant from the Cancer Prevention and Research Institute of Texas. This collaborative approach enhances Hummingbird's capacity to deliver effective therapies for patients with challenging medical conditions.

ADCendo ApS is a biotechnology company focused on developing innovative anti-cancer drugs through the use of antibody-drug conjugates (ADCs). The company targets novel receptors that are overexpressed in various cancer types, addressing significant unmet medical needs in the field of oncology. Its ADCs aim to provide targeted therapy for patients suffering from aggressive cancers such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, as well as other carcinomas including those of the breast, colon, pancreas, prostate, ovary, and kidney. Through its research and development efforts, ADCendo strives to create effective treatment options for patients facing challenging cancer diagnoses.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

Altasciences is a mid-sized contract research organization based in Laval, Quebec, that provides a comprehensive range of services to pharmaceutical and biotechnology companies. The company specializes in preclinical and clinical pharmacology studies, offering support in drug formulation, manufacturing, and analytical services. Altasciences' integrated solutions encompass preclinical safety testing, clinical pharmacology, proof of concept studies, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management. These services are tailored to meet the specific needs of sponsors, facilitating more informed and efficient early drug development decisions. By streamlining the early-phase clinical research process, Altasciences aims to accelerate the delivery of better drugs to patients.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Reneo Pharmaceuticals is a clinical-stage pharmaceutical company based in San Diego, California, that focuses on developing therapies for patients with rare genetic mitochondrial diseases. These conditions are linked to defects in energy metabolism, leading to issues such as muscle weakness and wasting. The company is developing REN001, an oral drug designed to modulate genes involved in mitochondrial function, aiming to enhance adenosine triphosphate (ATP) production, which is essential for cellular energy. By improving mitochondrial activity, Reneo seeks to enhance the daily functioning and quality of life for patients suffering from these disorders. Founded in 2014, Reneo Pharmaceuticals is committed to addressing the needs of individuals with orphan metabolic diseases.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Rappta Therapeutics is a lead-optimization stage biopharmaceutical company. We are working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A).

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.

Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders that involve neuronal imbalance. The company is advancing several lead product candidates, including PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator currently in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective small molecule inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is developing PRAX-562, a persistent sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, as well as PRAX-222, an antisense oligonucleotide targeting SCN2A epilepsy. The company also has a program for treating KCNT1 gain-of-function epilepsy. Established in 2015 and based in Cambridge, Massachusetts, Praxis collaborates with other organizations through various agreements to enhance its research and development efforts.

Freeline Therapeutics is a clinical-stage biotechnology company focused on developing innovative adeno-associated virus (AAV) vector-mediated gene therapies aimed at treating inherited systemic diseases. The company employs engineered AAV vectors and capsids, alongside novel promoters and transgenes, to introduce functional copies of therapeutic genes into human liver cells. This process allows for the production of essential proteins in the bloodstream, addressing deficiencies caused by genetic disorders. Freeline's key product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1. Their ongoing development programs encompass various clinical trials to advance these gene therapies and provide transformative solutions for patients suffering from debilitating conditions.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.

WCG is a company focused on accelerating the delivery of new treatments and therapies in the biopharmaceutical sector. It serves biopharmaceutical companies, contract research organizations (CROs), and health institutions by providing a range of services designed to enhance clinical and technological processes. These services include study planning, site optimization, patient engagement, and scientific and market insight solutions. By supporting organizations that develop products and therapies, WCG aims to improve human health and facilitate the efficient advancement of medical innovations.

Allievex Corporation is a clinical-stage biotechnology company based in Marblehead, Massachusetts, focused on developing and commercializing innovative therapeutics for rare pediatric neurodegenerative diseases. Founded in 2018, the company is advancing an investigational enzyme replacement therapy known as tralesinidase alfa, which combines recombinant human alpha-N-acetyglucosaminidase with a peptide derived from insulin-like growth factor 2. This therapy aims to provide treatment options for children suffering from Sanfilippo syndrome type B and mucopolysaccharidosis IIIB, both of which are severe conditions that significantly impact neurological function.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Arcellx is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with cancer and other incurable diseases. The company aims to enhance the safety, effectiveness, and accessibility of these therapies. Its lead product candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma and is currently undergoing a Phase 1 clinical study. This therapy has received multiple designations from the U.S. Food and Drug Administration, including Fast Track and Orphan Drug status. Additionally, Arcellx is advancing its controllable CAR-T therapy, ARC-SparX, through two clinical programs aimed at treating relapsed or refractory multiple myeloma and acute myeloid leukemia.

Glycomine, Inc. is a biotech company focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation, which can severely impact patients' health. Established in 2014 and located in San Carlos, California, Glycomine aims to address the significant unmet medical need for effective treatments in the realm of rare diseases, where approximately 95% lack any FDA-approved therapies. The company specializes in creating replacement therapies that utilize a combination of substrates, enzymes, and proteins, delivered through bio-nano materials that target specific cells within clinically relevant organs. By innovating in this area, Glycomine seeks to provide new therapeutic options for patients suffering from disorders of metabolism and protein misfolding.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in gene and cell therapy. It is recognized for its expertise in lentiviral vector technology, which allows for the integration of therapeutic genes into non-dividing cells, including neurons and retinal cells. The company operates in two main segments: Platform and Product. The Platform segment focuses on bioprocessing and development services for third parties, while the Product segment is dedicated to the clinical and preclinical development of gene and cell therapies targeting a range of diseases, particularly those affecting the ocular and central nervous system. Oxford BioMedica's product pipeline includes several candidates, such as OXB-302 for haematological tumors and OXB-203 for wet age-related macular degeneration, among others. The company has established partnerships with major pharmaceutical firms, including Novartis and Bristol Myers Squibb, to enhance its research and development efforts. Founded in 1995, Oxford BioMedica aims to transform treatment options for diseases with limited or no existing therapies.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Galecto is a clinical-stage biotechnology company focused on developing small molecules to treat severe diseases, particularly fibrosis and cancer. The company’s lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 aimed at addressing severe fibrotic lung diseases, including idiopathic pulmonary fibrosis, which presents a significant unmet medical need. Founded in 2011, Galecto builds upon more than a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company also develops additional therapeutics, such as GB1211, a selective oral galectin-3 inhibitor targeting fibrosis related to non-alcoholic steatohepatitis. Galecto's strong patent portfolio and research foundation position it uniquely within the therapeutic landscape for fibrosis and related diseases.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies aimed at treating serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer. The company specializes in creating small molecule inhibitors that target various integrins. By leveraging insights into integrin biology, Morphic Therapeutic is building a pipeline of innovative therapeutics designed to address a range of immunological, fibrotic, neoplastic, and vascular diseases, thereby offering potential new treatment options for patients with significant unmet medical needs.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company focuses on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. This next-generation insulin sensitizer aims to address the underlying pathophysiology of NASH, a condition characterized by fat accumulation and inflammation in the liver that can lead to severe complications such as cirrhosis and liver cancer. Cirius Therapeutics is committed to providing innovative solutions to healthcare providers for managing liver and metabolic diseases.

ReViral is a developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with respiratory syncytial virus (RSV) by developing novel compounds.

Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, focused on developing and commercializing etripamil for various cardiovascular conditions. Etripamil is a novel short-acting calcium channel blocker designed to be administered as a rapid-onset nasal spray, specifically targeting the termination of episodes of paroxysmal supraventricular tachycardia (PSVT). The company is currently conducting Phase III clinical trials for etripamil in the treatment of PSVT and is also exploring its potential applications for atrial fibrillation, angina, and other related cardiovascular disorders. Founded in 2003, Milestone Pharmaceuticals aims to address unmet medical needs in cardiovascular disease management through innovative therapeutic solutions.

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.

Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company focuses on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. This next-generation insulin sensitizer aims to address the underlying pathophysiology of NASH, a condition characterized by fat accumulation and inflammation in the liver that can lead to severe complications such as cirrhosis and liver cancer. Cirius Therapeutics is committed to providing innovative solutions to healthcare providers for managing liver and metabolic diseases.

ConvaTec Inc. is a global medical technology company based in Bridgewater, New Jersey, that specializes in manufacturing and marketing medical products and services for the management of chronic conditions. Founded in 1978, the company offers a range of therapies, including advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products are designed to improve the quality of life for patients and support caregivers in managing various health challenges effectively. As a subsidiary of Convatec Group Plc, ConvaTec continues to focus on innovation and excellence in its medical offerings.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, established in 2014. The company specializes in discovering and developing innovative therapies aimed at enhancing anti-tumor immune responses. Its technology platform focuses on the selective delivery of small molecule drugs to tumor-associated macrophages, which activates the body's natural immune system to combat cancer. By harnessing this targeted approach, Macrophage Pharma aims to improve treatment outcomes for patients facing cancer.

Arch Oncology, Inc. is an immuno-oncology company focused on discovering and developing antibody therapeutics for the treatment of solid tumors and hematologic cancers. Established in 2006 and headquartered in Brisbane, California, with a research laboratory in St. Louis, Missouri, the company specializes in anti-CD47 antibodies that represent a novel class of checkpoint inhibitors. These second-generation antibodies are designed to engage both the adaptive and innate immune systems, effectively targeting and killing tumor cells. By harnessing the body's immune response, Arch Oncology aims to provide new treatment options for patients battling cancer.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. The company utilizes a microRNA-based target discovery platform to identify novel RNA dysregulated cancer drivers, which can be addressed by small molecules and biologics. Inspirna's clinical programs include first-in-class oral small molecules aimed at treating patients with RAS mutant colorectal cancer (RGX-202) and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) (RGX-104), both currently in Phase 1b/2 trials. Through its research, Inspirna aims to provide effective treatment options that specifically target cancer metabolism and progression, offering potential advancements in cancer care.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Entasis Therapeutics is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for serious infections caused by multidrug-resistant Gram-negative bacteria, a growing global health concern. The company’s anti-infective discovery platform has led to a diverse pipeline of differentiated drug candidates, including ETX2514SUL and SUL-DUR, which target Acinetobacter baumannii, zoliflodacin for Neisseria gonorrhoeae, and ETX0282CPDP aimed at Enterobacterales. Additionally, ETX0462 is being developed to address infections caused by Pseudomonas. Through its focused efforts, Entasis Therapeutics aims to provide effective solutions for patients suffering from these challenging bacterial infections.

Outpost Medicine, founded in 2016 and based in the United States, focuses on developing innovative therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to addressing gastrointestinal and urologic conditions, with its lead clinical-stage product candidate, OP-233, aimed at treating stress urinary incontinence (SUI), a condition characterized by involuntary urine loss during physical activities. Additionally, Outpost is working on treatments for overactive bladder (OAB) and irritable bowel syndrome (IBS), reflecting its commitment to advancing healthcare solutions in these areas.

Minervax is focused on developing a vaccine to prevent infections caused by Group B streptococcus (GBS), which can lead to serious health issues in newborns and adverse pregnancy outcomes. The company is researching a specific fusion protein that has demonstrated the ability to stimulate strong protective immunity against various clinically significant GBS strains. By utilizing this innovative approach, Minervax aims to provide medical professionals with an effective tool to protect newborns from potentially life-threatening bacterial infections associated with GBS.

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, dedicated to developing innovative therapies that aim to enhance the effectiveness of radiotherapy in cancer treatment. The company’s lead product candidate, avasopasem manganese (GC4419), is a small molecule dismutase mimetic currently undergoing Phase III clinical trials for the treatment of severe oral mucositis induced by radiation in patients with head and neck cancer. Additionally, it is being tested in Phase IIa trials for radiotherapy-induced esophagitis in lung cancer patients. Galera is also advancing a second candidate, GC4711, which is in Phase I/II trials targeting pancreatic and lung cancers. The company was founded in 2012 and is committed to addressing severe side effects associated with cancer treatments to improve patient outcomes.

Synlab is a provision of medical diagnostic services with a complete offer of laboratory medicine services for patients, doctors, clinics, and the pharmaceutical industry. They provide services that include laboratory analysis, synlab iunic, clinical diagnostic services, business services, service and professionals, and genetic analysis.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.